Ivosidenib Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top Countries — Revenue
Access the full forecast model.
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
Ivosidenib Market Analysis — Presence
Geographical Analysis
Click countries to exploreRegional and Country Analysis
Global Ivosidenib Market Analysis 2026
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| Global | $ 124.6 Million | $ 150.3 Million | $ 218.7 Million | 4.8% |
| North America | $ 35.51 Million | $ 42.39 Million | $ 61.02 Million | 4.66% |
| United States | $ 28.52 Million | $ 33.95 Million | $ 48.69 Million | 4.611% |
| Canada | $ 4.94 Million | $ 5.72 Million | $ 8.18 Million | 4.563% |
| Mexico | $ 2.06 Million | $ 2.71 Million | $ 4.15 Million | 5.456% |
| Europe | $ 33.27 Million | $ 39.83 Million | $ 56.86 Million | 4.551% |
| United Kingdom | $ 5.52 Million | $ 6.45 Million | $ 9.04 Million | 4.307% |
| France | $ 3.76 Million | $ 4.42 Million | $ 6.14 Million | 4.193% |
| Germany | $ 7.54 Million | $ 8.94 Million | $ 12.71 Million | 4.492% |
| Italy | $ 2.5 Million | $ 2.91 Million | $ 4.09 Million | 4.371% |
| Russia | $ 3.89 Million | $ 4.58 Million | $ 6.37 Million | 4.206% |
| Spain | $ 2.8 Million | $ 3.19 Million | $ 4.49 Million | 4.387% |
| Sweden | $ 0.83 Million | $ 0.88 Million | $ 1.02 Million | 1.961% |
| Denmark | $ 0.77 Million | $ 0.8 Million | $ 0.97 Million | 2.448% |
| Switzerland | $ 0.67 Million | $ 0.72 Million | $ 0.91 Million | 3.023% |
| Luxembourg | $ 0.57 Million | $ 0.6 Million | $ 0.74 Million | 2.697% |
| Rest of Europe | $ 4.44 Million | $ 6.35 Million | $ 10.38 Million | 6.326% |
| Asia Pacific | $ 40.99 Million | $ 49.75 Million | $ 74.58 Million | 5.191% |
| China | $ 15.54 Million | $ 19 Million | $ 28.71 Million | 5.294% |
| Japan | $ 4.47 Million | $ 5.27 Million | $ 7.61 Million | 4.686% |
| South Korea | $ 2.13 Million | $ 2.49 Million | $ 3.51 Million | 4.38% |
| India | $ 7.3 Million | $ 8.96 Million | $ 13.65 Million | 5.408% |
| Australia | $ 1.07 Million | $ 1.14 Million | $ 1.64 Million | 4.608% |
| Singapore | $ 0.74 Million | $ 0.75 Million | $ 0.97 Million | 3.326% |
| Taiwan | $ 1.27 Million | $ 1.44 Million | $ 2.01 Million | 4.255% |
| South East Asia | $ 3.4 Million | $ 4.03 Million | $ 5.97 Million | 5.027% |
| Rest of APAC | $ 5.08 Million | $ 6.67 Million | $ 10.52 Million | 5.862% |
| South America | $ 5.98 Million | $ 6.91 Million | $ 9.4 Million | 3.92% |
| Brazil | $ 2.56 Million | $ 2.98 Million | $ 4.08 Million | 4.01% |
| Argentina | $ 1.03 Million | $ 1.18 Million | $ 1.58 Million | 3.767% |
| Colombia | $ 0.48 Million | $ 0.54 Million | $ 0.72 Million | 3.583% |
| Peru | $ 0.27 Million | $ 0.28 Million | $ 0.38 Million | 3.6% |
| Chile | $ 0.23 Million | $ 0.24 Million | $ 0.3 Million | 2.763% |
| Rest of South America | $ 1.42 Million | $ 1.69 Million | $ 2.35 Million | 4.183% |
| Middle East | $ 6.85 Million | $ 8.72 Million | $ 13.01 Million | 5.135% |
| Saudi Arabia | $ 1.39 Million | $ 1.8 Million | $ 2.72 Million | 5.325% |
| Turkey | $ 1.61 Million | $ 2.03 Million | $ 2.99 Million | 4.965% |
| UAE | $ 1.28 Million | $ 1.66 Million | $ 2.52 Million | 5.409% |
| Egypt | $ 0.98 Million | $ 1.22 Million | $ 1.8 Million | 4.946% |
| Qatar | $ 0.44 Million | $ 0.54 Million | $ 0.77 Million | 4.485% |
| Rest of Middle East | $ 1.15 Million | $ 1.47 Million | $ 2.21 Million | 5.213% |
| Africa | $ 1.99 Million | $ 2.71 Million | $ 3.83 Million | 4.432% |
| East Africa | xxxx | xxxx | xxxx | xxxx |
| West Africa | xxxx | xxxx | xxxx | xxxx |
| North Africa | xxxx | xxxx | xxxx | xxxx |
| South Africa | $ 0.98 Million | $ 1.32 Million | $ 1.86 Million | 4.324% |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Segmentation Analysis
Ivosidenib Patient Type Segment Analysis According to Cognitive Market Research, adults hold a prominent market share. Ivosidenib's effectiveness in treating relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation is fueling the market's notable increase in the adult segment. Because adult patients with AML are the majority affected, there is a growing need for tailored treatments like Ivosidenib. Its ability to achieve remission and extend longevity in this patient population drives the rise of its market. Pediatric is the fastest-growing category over the forecast period. Due to its potential efficacy in treating children patients with relapsed or refractory acute myeloid leukemia (AML) having an isocitrate dehydrogenase-1 (IDH1) mutation, the pediatric segment is emerging as a prominent driver of growth in the Ivosidenib market. Due to its capacity to induce remission and enhance survival rates in this particular patient population, ivosidenib is becoming more and more popular as a treatment for juvenile acute myeloid leukemia. Adult Pediatric
Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.
To learn more about market share and segmentation, request the free sample pages.
Competitor Analysis
Competitive Landscape of the Ivosidenib Market
Key players deploy strategic initiatives such as product innovations, partnerships, and mergers. Companies prioritize R&D to introduce cutting-edge reagents, ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Agios Pharmaceuticals | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →Report Scope & Analysis
According to Cognitive Market Research, The Global Ivosidenib market size is USD 18.5 million in 2024 and will expand at a compound annual growth rate (CAGR) of 4.20% from 2024 to 2031.
- North America Ivosidenib Market held 40% of the global revenue with a market size of USD 7.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.4% from 2024 to 2031.
- Europe Ivosidenib Market held 30% of the global market size of USD 5.55 million in 2024.
- Asia Pacific Ivosidenib Market held 23% of the global revenue with a market size of USD 4.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
- South America Ivosidenib market held 5% of the global revenue with a market size of USD 0.93 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.6% from 2024 to 2031.
- Middle East and Africa Ivosidenib Market held 2% of the global revenue with a market size of USD 0.37 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.9% from 2024 to 2031.
- Ivosidenib is now more readily available to patients thanks to advantageous payment rules in a number of nations, including the US and Europe.
- Ivosidenib's market reach may be increased as it is presently being studied in clinical studies for additional FLT3-driven malignancies, namely chronic myeloid leukemia (CML).
Introduction of the Ivosidenib Market
Ivosidenib is an oral inhibitor of isocitrate dehydrogenase 1 (IDH1), a mutant enzyme in some malignancies, most notably acute myeloid leukemia (AML). It is marketed under the brand name Tibsovo. Ivosidenib was approved by the FDA in 2018 to treat individuals with an IDH1 mutation who have relapsed or are refractory to AML. Ivosidenib blocks the mutant enzyme, which stops uncontrollably large cell growth. With a focused therapy approach available for a particular genetic subset of AML patients, its approval represented a significant leap in precision medicine. Ivosidenib is a promising treatment for cancer that highlights the increasing significance of molecularly focused medicines in cancer care, especially when it comes to targeting specific genetic abnormalities that cause cancer.
Analyst Conclusion
- Author's Say's, The global Ivosidenib market will expand significantly by 4.20% CAGR between 2024 to 2031.
- Ivosidenib is now more readily available to patients thanks to advantageous payment rules in a number of nations, including the US and Europe.
- Ivosidenib's market reach may be increased as it is presently being studied in clinical studies for additional FLT3-driven malignancies, namely chronic myeloid leukemia (CML).
- The 30 Tablets held the highest Ivosidenib market revenue share in 2024.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
Frequently Asked Questions
★ Reviews
Rate this report
Ivosidenib Market Analysis — Table of Contents
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
| Patient Type | Adult, Pediatric |
|---|---|
| End-User | Clinics, Homecare, Ambulatory Surgical Centers |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
| List of Competitors | Agios Pharmaceuticals |
Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))
- 1.1 Top Competitors Analysis
- 1.1.1 Global Ivosidenib Market Analysis by Key Players
- 1.1.2 Segment Market Analysis by Key Players
- 1.1.3 Top Players Ranking 2024
- 1.1.4 New Product Launch Analysis
- 1.1.5 Industry Mergers and Acquisition Analysis
- 1.2 Company Profile (Data Subject to Availability) Sample Format
- 1.2.1 Agios Pharmaceuticals
- 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.1.2 Business Overview
- 1.2.1.3 Financials (Subject to data availability)
- 1.2.1.4 R&D Investment (Subject to data availability)
- 1.2.1.5 Product Types Specification
- 1.2.1.6 Business Strategy
- 1.2.1.7 Recent Developments
- 1.2.1.8 Management Change
- 1.2.1.9 S.W.O.T Analysis
- 1.2.1 Agios Pharmaceuticals
- 1.1 Top Competitors Analysis
Chapter 2. Global Ivosidenib Market Analysis
- 2.1 Global Ivosidenib Market Analysis
- 2.2 Global Ivosidenib Market Analysis by Region
- 2.3 Global Ivosidenib Market Analysis by Patient Type
- 2.4 Global Ivosidenib Market Analysis by End-User
- 2.5 Global Ivosidenib Market Analysis by Distribution Channel
- 2.6 Global Ivosidenib Market Analysis by Key Players
Chapter 3. North America Ivosidenib Market Analysis
- 3.1 North America Ivosidenib Market Analysis
- 3.2 North America Ivosidenib Market Analysis by Country
- 3.3 North America Ivosidenib Market Analysis by Patient Type
- 3.4 North America Ivosidenib Market Analysis by End-User
- 3.5 North America Ivosidenib Market Analysis by Distribution Channel
- 3.6 North America Ivosidenib Market Analysis by Key Players
Chapter 4. Europe Ivosidenib Market Analysis
- 4.1 Europe Ivosidenib Market Analysis
- 4.2 Europe Ivosidenib Market Analysis by Country
- 4.3 Europe Ivosidenib Market Analysis by Patient Type
- 4.4 Europe Ivosidenib Market Analysis by End-User
- 4.5 Europe Ivosidenib Market Analysis by Distribution Channel
- 4.6 Europe Ivosidenib Market Analysis by Key Players
Chapter 5. Asia Pacific Ivosidenib Market Analysis
- 5.1 Asia Pacific Ivosidenib Market Analysis
- 5.2 Asia Pacific Ivosidenib Market Analysis by Country
- 5.3 Asia Pacific Ivosidenib Market Analysis by Patient Type
- 5.4 Asia Pacific Ivosidenib Market Analysis by End-User
- 5.5 Asia Pacific Ivosidenib Market Analysis by Distribution Channel
- 5.6 Asia Pacific Ivosidenib Market Analysis by Key Players
Chapter 6. South America Ivosidenib Market Analysis
- 6.1 South America Ivosidenib Market Analysis
- 6.2 South America Ivosidenib Market Analysis by Country
- 6.3 South America Ivosidenib Market Analysis by Patient Type
- 6.4 South America Ivosidenib Market Analysis by End-User
- 6.5 South America Ivosidenib Market Analysis by Distribution Channel
- 6.6 South America Ivosidenib Market Analysis by Key Players
Chapter 7. Middle East Ivosidenib Market Analysis
- 7.1 Middle East Ivosidenib Market Analysis
- 7.2 Middle East Ivosidenib Market Analysis by Country
- 7.3 Middle East Ivosidenib Market Analysis by Patient Type
- 7.4 Middle East Ivosidenib Market Analysis by End-User
- 7.5 Middle East Ivosidenib Market Analysis by Distribution Channel
- 7.6 Middle East Ivosidenib Market Analysis by Key Players
Chapter 8. Africa Ivosidenib Market Analysis
- 8.1 Africa Ivosidenib Market Analysis
- 8.2 Africa Ivosidenib Market Analysis by Country
- 8.3 Africa Ivosidenib Market Analysis by Patient Type
- 8.4 Africa Ivosidenib Market Analysis by End-User
- 8.5 Africa Ivosidenib Market Analysis by Distribution Channel
- 8.6 Africa Ivosidenib Market Analysis by Key Players
Chapter 9. Patient Type Analysis
- 9.1 Adult
- 9.1.1 Global Adult Market
- 9.1.2 Global Adult Market by Region
- 9.2 Pediatric
- 9.2.1 Global Pediatric Market
- 9.2.2 Global Pediatric Market by Region
- 9.1 Adult
Chapter 10. End-User Analysis
- 10.1 Clinics
- 10.1.1 Global Clinics Market
- 10.1.2 Global Clinics Market by Region
- 10.2 Homecare
- 10.2.1 Global Homecare Market
- 10.2.2 Global Homecare Market by Region
- 10.3 Ambulatory Surgical Centers
- 10.3.1 Global Ambulatory Surgical Centers Market
- 10.3.2 Global Ambulatory Surgical Centers Market by Region
- 10.1 Clinics
Chapter 11. Distribution Channel Analysis
- 11.1 Hospital Pharmacies
- 11.1.1 Global Hospital Pharmacies Market
- 11.1.2 Global Hospital Pharmacies Market by Region
- 11.2 Retail Pharmacies
- 11.2.1 Global Retail Pharmacies Market
- 11.2.2 Global Retail Pharmacies Market by Region
- 11.3 Online Pharmacies
- 11.3.1 Global Online Pharmacies Market
- 11.3.2 Global Online Pharmacies Market by Region
- 11.1 Hospital Pharmacies
Chapter 12. Qualitative Analysis (Subject to Data Availability)
- 12.1 Market Drivers
- 12.2 Market Restraints
- 12.3 Market Trends
- 12.4 Market Opportunity
- 12.5 Technological Road Map (Subject to Data Availability)
- 12.6 Product Life Cycle (Subject to Data Availability)
- 12.7 Customer and Buyer Behavior Analysis
- 12.7.1 Digital Engagement, Customer Experience & Relationship Analysis
- 12.7.2 Customer Buying Behavior & Purchase Decision Analysis
- 12.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
- 12.7.4 Pricing, Affordability & Value Perception Analysis
- 12.7.5 Customer Segmentation & Demand Pattern Analysis
- 12.8 PESTEL Analysis
- 12.8.1 Political Factors
- 12.8.2 Economic Factors
- 12.8.3 Social Factors
- 12.8.4 Technological Factors
- 12.8.5 Legal Factors
- 12.8.6 Environmental Factors
- 12.9 Industrial Chain Analysis (Subject to Data Availability)
- 12.9.1 Industry Chain Analysis
- 12.9.2 Manufacturing Cost Analysis
- 12.9.3 Supply Side Analysis
- 12.9.3.1 Raw Material Analysis
- 12.9.3.2 Raw Material Procurement Analysis
- 12.9.3.3 Raw Material Price Trend Analysis
- 12.10 Porter’s Five Forces Analysis
- 12.10.1 Bargaining Power of Suppliers
- 12.10.2 Bargaining Power of Buyers
- 12.10.3 Threat of New Entrants
- 12.10.4 Threat of Substitutes
- 12.10.5 Degree of Competition
- 12.11 Patent Analysis (Subject to Data Availability)
- 12.12 ESG Analysis
- 12.13 Geopolitical Outlook
- 12.13.1 Global Power Realignment & Strategic Alliances
- 12.13.2 Geopolitical Risk Landscape & Conflict Hotspots
- 12.13.3 International Trade Relations & Market Access Environment
- 12.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
- 12.13.5 Supply Chain Resilience, Localization & Resource Nationalism
- 12.13.6 Technology Sovereignty & Digital Geopolitics
- 12.13.7 Strategic Implications for Investment, Growth & Market Entry
- 12.14 AI & Market Transformation
- 12.14.1 Competitive Landscape Disruption & Strategic Shifts
- 12.14.2 AI-Driven Transformation of Industry Value Chain
- 12.14.3 Evolution of Business Models & Revenue Streams
- 12.14.4 AI-Driven Product, Service & Innovation Transformation
- 12.14.5 Customer Behavior, AI Adoption & Future Market Evolution
Chapter 13. TOP 10 Country Analysis
- 13.1 Country 1
- 13.2 Country 2
- 13.3 Country 3
- 13.4 Country 4
- 13.5 Country 5
- 13.6 Country 6
- 13.7 Country 7
- 13.8 Country 8
- 13.9 Country 9
- 13.10 Country 10
Chapter 14. Research Findings
- 14.1 Key Takeaways
- 14.2 Analyst Point of View
- 14.3 Assumptions and Acronyms
Chapter 15. Research Methodology and Sources
- 15.1 Primary Data Collection
- 15.1.1 Steps for Primary Data Collection
- 15.1.1.1 Identification of KOL
- 15.1.2 Backward Integration
- 15.1.3 Forward Integration
- 15.1.4 How Primary Research Help Us
- 15.1.5 Modes of Primary Research
- 15.1.1 Steps for Primary Data Collection
- 15.2 Secondary Research
- 15.2.1 How Secondary Research Help Us
- 15.2.2 Sources of Secondary Research
- 15.3 Data Validation
- 15.3.1 Data Triangulation
- 15.4 Data Representation
- 15.1 Primary Data Collection
Athenaeum AI Dashboard
Our Proprietary Methodology
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Ivosidenib Market Analysis Market analysis.
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
Data Assurance Metrics
Analytical Coverage
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Sources from the Pharma and Healthcare Industry
The Three Pillars of End-to-End Market Research Services
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Ivosidenib Market Analysis market.
Market Survey
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the ivosidenib market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
- Buyer intent & sentiment analysis
- Purchase cycle mapping
- Price sensitivity research
- Channel preference profiling
- Competitive perception study
Customized Market Data & Reports
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
- Ready syndicate report
- Custom data scope & segmentation
- Excel quantitative models
- Board-ready PPT with key findings
- Secure cloud portal access
Strategic Consultation
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
- Dedicated analyst assigned to you
- Live walkthrough of findings
- Strategic Q&A sessions
- Go-to-market recommendations
- NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
